AN INNOVATIVE THERAPEUTIC STRATEGY
To fight bacterial antimicrobial
resistance by stimulating the immune response and boosting the expression
of natural human antimicrobial peptides thanks to marine bioinspired molecules.
ABOUT
ANTIMICROBIAL
RESISTANCE
Antimicrobial resistance (AMR) is a worldwide health threat and considered by the World Health Organization to be one of the top global health priorities. In 2019, it was attributed 1.27 million deaths around the world, with 35.000 deaths per year in the United States and 33.000 in the European Union. Since the clinical pipeline of new antimicrobials is largely dry, the development of new and innovative therapeutic strategies to fight infections and reduce spread of antimicrobial resistance is urgently needed.
ALL
Countries
4.95 M
Deaths associated
with AMR
Related cases
1.27 M
Deaths directly
attribuable to AMR
Related deaths
Related cases
Related deaths
3.2 M€
Budget
JAN 2024
–
DEC 2027
Duration
Consortium
Duration
Consortium
ABOUT
MAXIMMUN
PROJECT
MaxImmun aims at selectively boosting expression of the body own antimicrobial defense peptides naturally produced at mucosal surfaces. The novelty of our approach is based on new immuno-modulatory molecules inducing a therapeutic expression of host antimicrobial peptides, without triggering inflammation. Rather than directly targeting a pathogen with exogeneous antibiotics and the risk of resistance development, our innovative therapeutic strategy fosters a natural endogenous response of the human body through its own antimicrobial defenses. Our approach provides a sustainable solution against antimicrobial resistance development that also protects from resistance spread in the environment and among animals.
CONSORTIUM
